Sources and further reading FDA evaluation of BPC-157-related bulk drug substances, 11 May 2026 FDA Pharmacy Compounding Advisory Committee briefing, July 2026 FDA: bulk drug substances that may present significant safety risks TGA and Australian Chief Medical Officer: unapproved peptide products, 19 June 2026 World Anti-Doping Agency: 2026 Prohibited List Early BPC research indexed by PubMed Review of BPC-157 and musculoskeletal soft-tissue healing Recent review calling for well-designed human trials Researcher, clinician or journalist
HEAL FASTER WITH BPC-157 THERAPY Support tissue repair, reduce inflammation, and accelerate recovery with BPC-157, your bodys natural protection compound
Examples include semaglutide (Ozempic, Wegovy) and tirzepatide (Zepbound, Mounjaro)
[1] There is no official clinical guidance regarding the concurrent use of lipotropic injections with tirzepatide, as Lipo C formulations are unapproved compounded products that have not been reviewed by the FDA
They function as chemical signals between cells, acting as hormones, neuromodulators, and growth factors [2]